A once-daily oral treatment with flexible dosing to manage adverse reactions1

For special warnings and precautions for use, please see the LORVIQUA SmPC.

  • Treatment with LORVIQUA should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.1
  • Detection of ALK-positive NSCLC is necessary for selection of patients for treatment with LORVIQUA 1
  • LORVIQUA should be swallowed whole, with or without food—never chewed, crushed, or split1
  • LORVIQUA is contraindicated in patients taking strong CYP3A4/5 inducers concomitantly* and in those with hypersensitivity to LORVIQUA or any of the excipients of LORVIQUA1
  • For patients taking LORVIQUA, alternative concomitant medicinal products with less potential to inhibit CYP3A4/5 should be considered1,*
  • Patients must avoid grapefruit products while taking LORVIQUA1
  • There are specific recommendations for dose modifications related to particular ARs1

 

*Please refer to the LORVIQUA SmPC for recommendations regarding the use of CYP3A4/5 inducers and CYP3A4/5 inhibitors.AR=adverse reaction; AV=atrioventricular; CNS=central nervous system; CYP3A4/5=cytochrome P450 3A4/5; ILD=interstitial lung disease; SmPC=Summary of Product Characteristics.ReferencesReference:

Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. 

Dosing & Therapy Management
LORVIQUA safety profile
Review the safety Loading
LORVIQUA efficacy
Discover the data Loading
PP-LOR-IRL-0076 February 2024 Legal Category S1A Further information available on request
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024